Hexarelin

Examorelin

Rank#999
Growth HormoneNot ApprovedAnimalResearchSubQ

Popular for:Most potent GHRP, cardioprotective effects, GH secretion research

288

Total Studies

168

Human Studies

Animal

Evidence Level

Not Approved

FDA Status

Overview

Hexarelin is the most potent synthetic growth hormone releasing peptide, producing the largest GH pulses among the GHRP family. It is a hexapeptide that was developed as a research tool for studying maximum GH secretion capacity.

Due to its potency, Hexarelin also produces the most significant effects on cortisol and prolactin levels compared to other GHRPs. It is subject to rapid desensitization with continuous use, typically requiring cycling protocols in research settings.

Mechanism of Action

Hexarelin acts as a potent ghrelin receptor agonist at GHS-R1a, producing maximal stimulation of somatotroph cells. It also has direct cardiac effects, interacting with a non-GHS-R1a receptor (CD36) in cardiac tissue, which has been studied for cardioprotective properties independent of GH release.

Key Research Benefits

Most potent GH release of any GHRP
Studied for cardioprotective effects via CD36 receptor
Researched for maximum GH secretion testing
May support lean body mass research
Unique cardiac receptor interaction distinguishes it from other GHRPs

Clinical Evidence Summary

Research Pipeline

Preclinical
Animal
Phase I
Phase II
Phase III
Approved

288

Total Studies

168

Human Studies

Not FDA-approved. Research compound. Primarily used in clinical research for GH secretion studies and cardiac research.

Key Studies / PubMed References

288 studies found on PubMed · showing top 25 by relevance

View all on PubMed

Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway.

In Vitro

Guan C, Li C, Shen X, et al. · European journal of medical research · 2023

PMID: 37710348

Hexarelin attenuates abdominal aortic aneurysm formation by inhibiting SMC phenotype switch and inflammasome activation.

Animal Study

Jiang B, Wang M, Li X, et al. · Microvascular research · 2022

PMID: 34856183

Ghrelin receptor agonist hexarelin attenuates antinociceptive tolerance to morphine in rats.

Animal Study

Baser T, Ozdemir E, Filiz AK, et al. · Canadian journal of physiology and pharmacology · 2021

PMID: 32893668

Hexarelin protects cardiac H9C2 cells from angiotensin II-induced hypertrophythe regulation of autophagy.

In Vitro

Agbo E, Li MX, Wang YQ, et al. · Die Pharmazie · 2019

PMID: 31526442

Modulation of PTEN by hexarelin attenuates coronary artery ligation-induced heart failure in rats.

Animal Study

Agbo E, Liu D, Li M, et al. · Turkish journal of medical sciences · 2019

PMID: 31091855

Side Effects & Safety

Significant cortisol elevation
Prolactin elevation
Rapid desensitization with continuous use (requires cycling)
Water retention
Appetite stimulation (less than GHRP-6)

Known Interactions

No curated interaction entry is live for Hexarelin yet.

Until the interaction table is fully populated, use the interaction checker and related peptides below to explore adjacent compounds and likely research pairings.

Frequently Asked Questions

Research Disclaimer

This page is for research and educational purposes only. The information presented is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Hexarelin is not approved by the FDA for human therapeutic use. Always consult a qualified healthcare professional before making any health-related decisions. The studies referenced are linked to their original PubMed sources for verification.